Tag
The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies
This Danish cohort study demonstrates that increased epicardial adipose tissue volume independently elevates the risk of new-onset atrial fibrillation, highlighting the importance of fat distribution beyond BMI in cardiovascular risk assess
A retrospective study shows high and fluctuating triglyceride-glucose (TyG) index trajectories predict increased short- and long-term mortality in ICU patients with atrial fibrillation, highlighting TyG dynamics as a valuable prognostic bio
This study reveals that fluctuating high triglyceride-glucose (TyG) index trajectories in critically ill atrial fibrillation patients significantly predict increased all-cause mortality up to one year post-ICU admission, offering a novel pr
Switching frail, elderly atrial fibrillation patients from warfarin to standard-dose DOAC reduced stroke, fatal and intracranial bleeding, and death, though gastrointestinal bleeding increased. Major bleeding and net clinical outcome remain
This study compares the effectiveness of the Marshall-Plan ablation strategy against pulmonary vein isolation for treating persistent atrial fibrillation.
The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor id
This randomized trial compares sedation regimens for pulsed-field ablation in atrial fibrillation, finding remimazolam-ketamine deep analgosedation superior to propofol-opioid approaches in reducing hypoxemia and hypotension.
The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.
The OPTIMAS trial shows that chronic kidney disease does not alter the safety or efficacy of early direct oral anticoagulant use after acute ischemic stroke with atrial fibrillation, supporting early initiation regardless of kidney status.
Early resumption of DOACs after serious bleeding in AF patients may lower stroke risk but significantly increases recurrent bleeding. Individualized decision-making and further research are recommended.
Extended daytime naps and inadequate nighttime sleep independently and synergistically elevate the risk of incident atrial fibrillation, according to a large Spanish cohort study.
